Document Type : Research Paper
Authors
Abstract
Samarium-153 is one of the most widely used radionuclides in preparation of pain palliation radiopharmaceuticals of bone metastases. Therefore, it is important to realize the types and amount of impurities in the products. The aim of this study is to evaluate the produced impurities (154Eu, 155Eu & 156Eu) both theoretically and experimentally. These impurities are produced in 153Sm preparation by irradiation of natural samarium. In the experiment, the gamma spectra are recorded at different time durations, as the half-lives of impurities are longer than 153Sm half-life. Moreover, a comparison is also given to show that the results of the experiment and that of theory are in good agreement with each other, where it gives an accurate assessment of the amount and the type of impurities.
Highlights
- M.A. Winston, “Radioisotope therapy in bone and joint diseases,” Sem. Nucl. Med. 9: 114-120 (1979).
- V.J. Lewington, “Targetted nuclear therapy for bone metastases,” Eur.J.Nucl. Med. 20: 66-74 (1993).
- N. Aldo Serafini, “Therapy of metastatic bone pain,” J. Nucl. Med. 42(6): 895-906 (2001).
- W.F. Goeckeler, B. Edwards, W.A. Volkert, R.A. Holmes, J. Simon, D. Wilson, “Skeletal localization of 153Sm chelates: Potential therapeutic agents,” J. Nucl. Med. 28: 495-504 (1987).
- W.A. Volkert, “153Sm-chelates: Potential therapeutic radiopharmaceuticals for the treatment of cancer in bone,” Indian J. Nucl. Med. 8: 12-19 (1993).
- K.W. Logan, W.A. Volkert, R.A. Holmes, “Radiation dose calculations in persons receiving ingections of 153Sm-EDTMP,” J. Nucl. Med. 28: 505-507 (1987).
- Neeta Pandit-Taskar, “Radiopharmaceutical therapy for palliation of bone pain from osseous metastases,” J. Nucl. Med. 45: 1358-1365 (2004).
- Production logistics and radionuclidic purity aspects of 153Sm for radionuclide therapy N. RAMAMOORTHY, 1,2,* P. SARASWATHY,1 M.K. DAS,3 K.S. MEHRA1 and M. ANANTHAKRISHNAN2. Received 4 June 2001, in revised form 30 August 2001 and accepted (30 August 2001).
- G. Friedlander, J.W. Kenedy, J.M. Miller, “Nuclear and Radiochemistry,” John Wiley & Sons, Inc, New York (1964).
- Yen Wang, “CRC Handbook of Radionuclides,” (1986).
Keywords
- M.A. Winston, “Radioisotope therapy in bone and joint diseases,” Sem. Nucl. Med. 9: 114-120 (1979).
- V.J. Lewington, “Targetted nuclear therapy for bone metastases,” Eur.J.Nucl. Med. 20: 66-74 (1993).
- N. Aldo Serafini, “Therapy of metastatic bone pain,” J. Nucl. Med. 42(6): 895-906 (2001).
- W.F. Goeckeler, B. Edwards, W.A. Volkert, R.A. Holmes, J. Simon, D. Wilson, “Skeletal localization of 153Sm chelates: Potential therapeutic agents,” J. Nucl. Med. 28: 495-504 (1987).
- W.A. Volkert, “153Sm-chelates: Potential therapeutic radiopharmaceuticals for the treatment of cancer in bone,” Indian J. Nucl. Med. 8: 12-19 (1993).
- K.W. Logan, W.A. Volkert, R.A. Holmes, “Radiation dose calculations in persons receiving ingections of 153Sm-EDTMP,” J. Nucl. Med. 28: 505-507 (1987).
- Neeta Pandit-Taskar, “Radiopharmaceutical therapy for palliation of bone pain from osseous metastases,” J. Nucl. Med. 45: 1358-1365 (2004).
- Production logistics and radionuclidic purity aspects of 153Sm for radionuclide therapy N. RAMAMOORTHY, 1,2,* P. SARASWATHY,1 M.K. DAS,3 K.S. MEHRA1 and M. ANANTHAKRISHNAN2. Received 4 June 2001, in revised form 30 August 2001 and accepted (30 August 2001).
- G. Friedlander, J.W. Kenedy, J.M. Miller, “Nuclear and Radiochemistry,” John Wiley & Sons, Inc, New York (1964).
- Yen Wang, “CRC Handbook of Radionuclides,” (1986).
', './data/nct/coversheet/cover_en.jpg'))